Molecular Partners AG

MOLN46

$5.51arrow_drop_down3.16%-$0.17

MOLN46

$5.51

arrow_drop_down3.16%-$0.17

Performance History

Key Stats
Open	$5.67
Prev. Close	$5.81
EPS	-2.16
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$209.59M
PE Ratio	-

	LOW	HIGH
Day Range	5.52	5.98
52 Week Range	3.32	12.70

Ratios







EPS	-2.16

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Molecular Partners AG (MOLN)

Molecular Partners AG (MOLN) is a biotechnology company specializing in the development of therapeutic proteins. The company's stock price history shows a volatile trend, with significant fluctuations over the years. Investors should carefully analyze the company's financial performance before making any investment decisions. MOLN is currently trading at ${INSERT STOCK PRICE}.

In recent news, Molecular Partners AG announced a collaboration with a leading pharmaceutical company to develop a novel treatment for a rare genetic disorder. This partnership is expected to drive future growth and potentially increase the company's market cap. MOLN has also received positive feedback from industry experts, who have praised the company's research and development efforts.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Patrick Amstutz Ph.D.
Headquarters: Schlieren
Employees: 175
Exchange: NASDAQ

Keep an eye on Molecular Partners AG

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Molecular Partners AG's (MOLN) price per share?

The current price per share for Molecular Partners AG (MOLN) is $5.51. The stock has seen a price change of -$0.18 recently, indicating a -3.16% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Molecular Partners AG (MOLN)?

For Molecular Partners AG (MOLN), the 52-week high is $12.7, which is 130.49% from the current price. The 52-week low is $3.32, the current price is 65.96% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Molecular Partners AG (MOLN) a growth stock?

Molecular Partners AG (MOLN) has shown an average price growth of -3.13% over the past three years. It has received a score of 21 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Molecular Partners AG as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Molecular Partners AG (MOLN) stock price performance year to date (YTD)?

As of the latest data, Molecular Partners AG (MOLN) has a year-to-date price change of 32.13%. Over the past month, the stock has experienced a price change of 16%. Over the last three months, the change has been -13.64%. Over the past six months, the figure is 55.31%.

help

Is Molecular Partners AG (MOLN) a profitable company?

Molecular Partners AG (MOLN) has a net income of -$61.98M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2.14K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $7.04M, although specific revenue growth data is currently not available. Operating income is noted at -$61.11M. Furthermore, the EBITDA is -$70.5M.

help

What is the market capitalization of Molecular Partners AG (MOLN)?

Molecular Partners AG (MOLN) has a market capitalization of $196.71M. The average daily trading volume is 5.59, indicating the stock's liquidity and investor engagement.

News

CALENDAR OF EVENTS

Jun 17, 2024

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

CALENDAR OF EVENTS

CLINICAL STUDY

Jun 14, 2024

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

CLINICAL STUDY

Jun 1, 2024

Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

MANAGEMENT STATEMENTS

CLINICAL STUDY

May 16, 2024

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

CLINICAL STUDY

Apr 29, 2024

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

About Molecular Partners AG (MOLN)

Keep an eye on Molecular Partners AG

Frequently Asked Questions

What is Molecular Partners AG's (MOLN) price per share?

What is the 52-week high and low for Molecular Partners AG (MOLN)?

Is Molecular Partners AG (MOLN) a growth stock?

What is Molecular Partners AG (MOLN) stock price performance year to date (YTD)?

Is Molecular Partners AG (MOLN) a profitable company?

What is the market capitalization of Molecular Partners AG (MOLN)?

News

Sign up for our newsletter

Take Your Investments to a Whole New Level